What changed in July for anyone importing herbal extracts — regulation, quality, supply and freight. The Extract Brief is our monthly desk note for procurement, QA and regulatory teams buying botanical ingredients from India. Each issue: the month's regulatory movement, one quality story worth understanding properly, price and freight direction, a knowledge-series explainer, and one ingredient in focus.
This Month in Three Lines
- Europe moved a step closer to a formal safety review of ashwagandha — the single largest Indian botanical export line.
- A new EU pesticide regulation names concentrates and extracts explicitly, with compliance from 29 January 2027.
- US tariffs on Indian goods settled at 18%, down from a peak of 50% — and freight kept softening.
Regulatory Watch
Ashwagandha edges toward an EU Article 8 review
On 14 July 2026, a meeting hosted at the European Parliament by MEP Sean Kelly formally launched Safeguard Ashwagandha, an industry initiative to place the botanical's peer-reviewed safety record in front of regulators before any formal assessment begins. The question on the table is whether ashwagandha faces an Article 8 review under Regulation (EC) 1925/2006 — the process that can end in restrictions, mandatory label warnings or a ban. No EFSA assessment has been opened yet. Separately, Australia's TGA issued an ashwagandha safety update on 20 July.
What buyers should do now: if ashwagandha is in your 2027 pipeline, ask your supplier today for species and plant-part authentication (root vs leaf), the withanolide assay method behind the label claim, and batch-level documentation that would stand up in a safety dossier. If a review opens, the suppliers who can produce that file quickly are the ones whose material keeps moving. Our ashwagandha regulatory guide and root-vs-leaf explainer cover the groundwork.
Regulation (EU) 2026/1546: the MRL rule that names extracts
Adopted 9 July 2026 and applicable from 29 January 2027, this regulation revises maximum residue levels for benomyl, carbendazim and thiophanate-methyl across fruits, vegetables, herbs, spices — and, explicitly, botanicals, concentrates and extracts. The recital states the quiet part plainly: concentration during drying or extraction can increase the commercial significance of residues.
This is the concentration-factor problem written into law. A raw herb that passes at 0.05 mg/kg can yield a 10:1 extract reading several times higher — both certificates are honest, but only one clears the border. Carbendazim is a recurring finding on Indian botanicals, so extract-level testing (not raw-material testing alone) is now the only defensible position. We unpack the arithmetic in our EU pesticide MRL compliance guide.
Novel Food: two sides of the line
The EU's mid-year position leaves ingredients on sharply different footing. Gotu kola, southern ginseng, wild oregano and white sage have been deemed novel in food supplements — unauthorised for EU sale without a novel food authorisation — while pomegranate extract was confirmed non-novel and remains freely marketable. Year to date the EU has issued 15 authorisations against 21 rejections. If your formulation touches the wrong side of that line, reformulation or market-scope decisions need to start now; see our pomegranate regulatory guide and brahmi vs gotu kola.
Also on the radar
- MOAH/MOSH maximum limits adopted 11 June 2026 — relevant to oleoresins and lipid-based extracts.
- Berberine: EFSA's public consultation on regulatory status remains open following its March launch.
- Monacolin K: a proposed ban decision is expected later in 2026.
- PFAS in food-contact packaging banned from 12 August 2026 — check drum-liner specifications with your packer.
- EU border controls: Regulation (EU) 2026/194 (January) removed Indian vanilla and cloves from increased-control listings on sustained compliance, and moved Piper peppers and dried Capsicum/Pimenta to 20% identity and physical checks; a June amendment (2026/1206) updated the annexes again — verify your commodity's current listing before shipment planning.
Quality Desk: What the Moringa Outbreak Actually Teaches
On 17 July 2026, the CDC and FDA closed their investigation into a multistate outbreak of extensively drug-resistant Salmonella traced to moringa leaf powder capsules: 34 illnesses, 11 hospitalisations, and recalls spanning product distributed from December 2025 through July 2026.
The useful lesson for buyers is not "avoid moringa" — it is that leaf powder and leaf extract are different microbiological propositions. Powder is dried plant material, often sun- or air-dried at origin, carrying whatever bioburden the field and drying yard left on it. A solvent-extracted, spray-dried extract has passed through processing steps hostile to vegetative pathogens. If you buy leaf-derived botanicals, specify total plate count, yeast and mould, and pathogen absence per 10 g — and ask how the material was treated, because steam sterilisation and ETO treatment have opposite consequences for an EU-bound shipment. Our moringa extract vs powder guide covers the decision in full.
Supply & Price Direction
Turmeric is firming. Indian mandi prices moved from roughly ₹13,900/quintal in early July to an August average near ₹14,900 — about 6% in a month, with Telangana and Andhra Pradesh accounting for half the planted area. Extract buyers should expect the move to reach curcumin 95% contract pricing on the usual one-quarter lag: Q4 quotes will carry it. Context in our turmeric sourcing guide.
Knowledge Series: Why Two Honest CoAs Can Disagree
Each issue of the Brief takes one recurring buyer question and treats it properly. This month: the assay method problem — the single most common source of specification disputes we see.
UV spectrophotometry measures everything in a sample that absorbs at the target wavelength, so it reads the whole actives complex — and anything else absorbing alongside it. HPLC separates the individual compounds and counts only the ones it names. Neither is wrong; they answer different questions. But a “40% by UV” and a “10% by HPLC” can describe the same powder, and a purchase order that states a number without a method is an invitation to a rejected shipment.
- Silymarin: UV vs HPLC — the classic case, unpacked below.
- Withanolides: gravimetric vs HPLC — the ashwagandha version of the same trap.
- Bacosides: HPLC vs UV — and why brahmi specs diverge.
- How to read a CoA — the full walkthrough, line by line.
- Supplier due-diligence checklist — the questions to ask before the first PO.
Ingredient in Focus: Milk Thistle
Milk thistle extract — the seed of Silybum marianum, standardised to silymarin — is one of the world's highest-volume liver-support ingredients, and the perfect illustration of this month's knowledge series. Silymarin is not one molecule but a flavonolignan complex: silybin A & B, isosilybin A & B, silychristin, silydianin. The market's workhorse grade is 80% silymarin by UV; the same material assayed by HPLC as silibinin typically reads near 30%. Two honest numbers, one powder — and the European and US pharmacopoeias quantify on the HPLC/silibinin basis.
Three things belong on every milk thistle specification. First, the method next to the number — never compare a UV figure against a competitor's HPLC figure. Second, an HPLC identity fingerprint: because silymarin content drives price, milk thistle is a known target for cutting with cheaper Carduus thistle seed, and a UV-only spec is the easiest to fool. Third, the EU-entry trio — heavy metals by ICP-MS, residual solvent limits, and non-ETO treatment status — which decides whether the shipment clears customs at all.
Demand context: the liver-health category keeps growing on the back of alcohol-alternative and metabolic-wellness positioning, and silymarin remains its anchor active. Go deeper: buyer's guide · regulatory compliance · sourcing guide · liver-health market · adulteration risks · silymarin research.
Sourcing milk thistle or ashwagandha this quarter?
Send us your specification — grade, method and destination market — and we'll respond within 24 hours.
Logistics & Trade
- US tariffs on Indian goods now stand at 18%, down from a peak of 50%, after the February interim India–US deal rescinded the 25% punitive tranche. India's AYUSH and herbal exports to the US ran about $689 million in FY2024–25, led by ashwagandha and turmeric.
- Freight softened through July. The Drewry World Container Index fell 4% to $4,374/FEU in the week ending 23 July; India–Europe spot sat around $3,500–4,500/FEU with Cape of Good Hope routing adding 10–14 days to transit.
- Structural, not cyclical: EU ETS reached 100% cost recovery in 2026, adding an estimated $150–400 per container on Asia–Europe lanes. That cost is permanent — worth building into landed-cost models now.
Dates for Your Diary
| Date | What Happens |
|---|---|
| 12 Aug 2026 | PFAS ban in EU food-contact packaging applies |
| Q3 2026 | EU consultation opens on harmonised vitamin & mineral maximum levels |
| Late 2026 | Monacolin K ban decision expected |
| 29 Jan 2027 | Regulation (EU) 2026/1546 pesticide MRLs apply — extracts in scope |
Sources for this issue include EUR-Lex, the US FDA and CDC, NutraIngredients and Drewry. Regulatory items are summarised for orientation — always verify against the official text before acting. Nothing here is legal advice.